Application of indobuprofen combined with clopidogrel in patients with ACS after PCI
Objective Studies have confirmed the efficacy and safety of post-operative acute coronary treatment with indomebufen and clopidroid(ACTE coronary syndrome,ACS)in patients with acute coronary syndrome.Methods Between June 2020 to March 2022,156 patients undergoing routine PCI treatment were enrolled,with the single combination divided into control groups(clopidgray endomebofen)and clopidgray aspirin,78 cases per patient group.The serum MCP-1 and S100A12 levels of the patients were measured and their main adverse cardiac events(MACE),drug intolerance and bleeding were recorded within 12 months.Results The clinical effectiveness rate in the observation group was 80.87%,significantly higher than that of control group 62.82%(χ2=6.205,P<0.05).In control group,there were 3 stroke cases,5 myocardial infarction cases and 3 cardiovascular deaths within 12 months.There were 1 stroke,3 myocardial infarction and 1 cardiovascular death in the observation group within 12 months.There were no differences in the two sets of comparisons(χ2=0.291,P>0.05).In one case in the control group,gastrointestinal disorders,in two cases a rash,and in one case asthma,patients in the control group showed no apparent drug tolerance and patients in the control group had better drug tolerance than the control group(P<0.05);There were 5 cases of insignificant bleeding,4 cases of minor bleeding,2 cases of acute bleeding in the control group,2 cases of insignificant bleeding,2 cases of minor bleeding without bleeding,1 case of minor bleeding without bleeding and 1 case of less bleeding than in the control group(χ2=6.281,P<0.05);Patients in the control group after treatment had levels of MCP-1 and S100A12 lower than those in the control group(t=17.942,14.016,P<0.05).Conclusion Post-operative treatment with indomebufen and clopidgray following PCI in patients with ACS is effective and safe,and can effectively reduce serum levels of MCP-1 and S100A12.
NETL
NSTL
万方数据
